Catheter Precision, Inc. (VTAK) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated October 10, 2025, details the results of a Special Meeting of stockholders held by Catheter Precision, Inc. The meeting addressed corporate governance and capital structure matters. The record date for the meeting was September 10, 2025.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the outcomes of shareholder voting.
Material Changes and Voting Results
Of the 1,487,266 shares outstanding, 641,616 shares (approximately 43.1%) were represented at the meeting. Stockholders approved three proposals:
- Proposal 1 (Authorized Share Increase): Approved an amendment to increase authorized common stock from 60 million to 500 million shares.
- Votes For: 497,162
- Votes Against: 133,882
- Abstentions: 10,571
- Proposal 2 (Auditor Ratification): Ratified the appointment of WithumSmith+Brown, PC as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Votes For: 610,134
- Votes Against: 16,778
- Abstentions: 14,703
- Proposal 3 (Adjournment): Approved the authority to adjourn or postpone the meeting to solicit additional votes if necessary.
- Votes For: 514,362
- Votes Against: 120,394
- Abstentions: 6,860
Guidance, Outlook, and Risks
The filing does not provide management commentary, financial guidance, or specific risk factors beyond the standard disclosure of the voting process. The approval of the share increase may impact future capital raising capabilities or dilution potential, though specific strategic intent is not detailed in this report.
Key Facts for Investor Verification
- Verify the effective date of the Certificate of Incorporation amendment to confirm the 500 million share authorization is legally active.
- Review the definitive proxy statement (Schedule 14A filed September 15, 2025) for detailed rationale behind the share increase.
- Monitor future filings for any immediate capital raises utilizing the newly authorized shares.
- Confirm the engagement terms with WithumSmith+Brown, PC for the 2026 fiscal year.